Comparative Pharmacology
Head-to-head clinical analysis: FLAGYL ER versus VANDAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAGYL ER versus VANDAZOLE.
FLAGYL ER vs VANDAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole, a nitroimidazole antibiotic, undergoes intracellular reduction by bacterial nitroreductases, forming cytotoxic compounds that damage DNA and inhibit nucleic acid synthesis, selectively targeting anaerobic bacteria and protozoa.
VANDAZOLE is a nitroimidazole antimicrobial agent that undergoes reduction by bacterial nitroreductases, forming cytotoxic free radicals that damage DNA and inhibit nucleic acid synthesis.
750 mg orally once daily for 10 days for bacterial vaginosis.
2 g orally as a single dose once daily for 2 days.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (increased to 10-12 hours with hepatic impairment; unchanged in renal impairment).
Approximately 8-10 hours in adults; prolonged to 20-25 hours in hepatic impairment.
Renal: 60-80% (metabolites and unchanged drug). Fecal: 6-15%. Minimal biliary.
Primarily renal (40-70% unchanged), with biliary/fecal elimination accounting for 15-20% as metabolites.
Category C
Category C
Nitroimidazole Antibiotic
Nitroimidazole Antibiotic